Busey Bank’s Standard BioTools LAB Stock Holding History

Busey Bank’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,594	Closed	-$14.3K	–	395
2026 Q1	$14.3K	Hold	15,594	–	–	﹤0.01%	372
2025 Q4	$20K	Buy	+15,594	New	+$20.9K	﹤0.01%	388

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Busey Bank's LAB Position: Q2 2026 in Review

Busey Bank sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 15,594 shares — an estimated $14.3K sold.

Busey Bank first reported a position in LAB in Q4 2025 and held it in 2 quarters. The position peaked at $20K in Q4 2025. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Busey Bank reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
Busey Bank sold 15,594 Standard BioTools shares in Q2 2026, an estimated $14.3K.
Busey Bank first reported a position in Standard BioTools in Q4 2025 and held it in 2 quarters.
Busey Bank's Standard BioTools position peaked at $20K in Q4 2025.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Busey Bank's 13F filing for Q2 2026, filed 13 Aug 2026.